IL31486A - Composition for the treatment of pathologically increased muscle tone containing a furazan derivative - Google Patents
Composition for the treatment of pathologically increased muscle tone containing a furazan derivativeInfo
- Publication number
- IL31486A IL31486A IL31486A IL3148669A IL31486A IL 31486 A IL31486 A IL 31486A IL 31486 A IL31486 A IL 31486A IL 3148669 A IL3148669 A IL 3148669A IL 31486 A IL31486 A IL 31486A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- composition
- muscle tone
- increased muscle
- pathologically increased
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 10
- 206010020852 Hypertonia Diseases 0.000 title description 4
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical class C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 title description 3
- 239000003158 myorelaxant agent Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000002082 anti-convulsion Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000011514 reflex Effects 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000001828 Gelatine Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 210000000426 patellar ligament Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- -1 sodium morpholine ethanolamine Chemical compound 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000892656 Ligusticum canadense Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- QLGLKGKYKXRALK-UHFFFAOYSA-N [Na].CC=C Chemical compound [Na].CC=C QLGLKGKYKXRALK-UHFFFAOYSA-N 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH125068 | 1968-01-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL31486A0 IL31486A0 (en) | 1969-03-27 |
| IL31486A true IL31486A (en) | 1972-07-26 |
Family
ID=4205989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL31486A IL31486A (en) | 1968-01-26 | 1969-01-24 | Composition for the treatment of pathologically increased muscle tone containing a furazan derivative |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US3577544A (OSRAM) |
| BE (1) | BE727363A (OSRAM) |
| DE (1) | DE1903569A1 (OSRAM) |
| FR (1) | FR2000802A1 (OSRAM) |
| GB (1) | GB1254893A (OSRAM) |
| IL (1) | IL31486A (OSRAM) |
| NL (1) | NL6900839A (OSRAM) |
-
1968
- 1968-02-02 US US702550A patent/US3577544A/en not_active Expired - Lifetime
-
1969
- 1969-01-17 NL NL6900839A patent/NL6900839A/xx unknown
- 1969-01-24 BE BE727363D patent/BE727363A/xx unknown
- 1969-01-24 DE DE19691903569 patent/DE1903569A1/de active Pending
- 1969-01-24 GB GB4113/69A patent/GB1254893A/en not_active Expired
- 1969-01-24 FR FR6901349A patent/FR2000802A1/fr not_active Withdrawn
- 1969-01-24 IL IL31486A patent/IL31486A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL31486A0 (en) | 1969-03-27 |
| NL6900839A (OSRAM) | 1969-07-29 |
| FR2000802A1 (OSRAM) | 1969-09-12 |
| GB1254893A (en) | 1971-11-24 |
| DE1903569A1 (de) | 1969-08-28 |
| BE727363A (OSRAM) | 1969-07-24 |
| US3577544A (en) | 1971-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI84556B (fi) | Foerfarande foer framstaellning av en formulation av kefaklor med laong verkan. | |
| US5153191A (en) | Cholecystokinin antagonists useful for treating depression | |
| Ross et al. | Cycloaliphatic Amino Acids in Cancer Chemotherspy | |
| KR920017650A (ko) | 하이드라존 유도체, 이의 제조방법 및 용도 | |
| NL8600302A (nl) | Farmaceutische preparaten met analgetische werkzaamheid, alsmede de bereiding en toepassing ervan. | |
| WO1987001036A1 (en) | Anticonvulsant compositions and method | |
| US3699230A (en) | Dimethylisosorbide solvent for muscle relaxant drugs | |
| Rasker et al. | Lack of beneficial effect of zinc sulphate in rheumatoid arthritis | |
| JPS6313967B2 (OSRAM) | ||
| JPS63130569A (ja) | カルボン酸アミド含有薬剤 | |
| IE891908L (en) | Novel esters | |
| IL31486A (en) | Composition for the treatment of pathologically increased muscle tone containing a furazan derivative | |
| US4061765A (en) | Polyhydroxyphenylchromanone salts and therapeutic composition | |
| US3959470A (en) | Psychotropic medicinal preparation | |
| KR900018100A (ko) | N-(5,6,7,8-테트라히드로피리도(2,3,-d)피리미딘-6-일-알카노일)-글루탐산 유도체 및 그의 제조방법 | |
| US3849562A (en) | Method of treating nephrosis | |
| US5234945A (en) | Method of producing body weight and food intake using a dopamine D2 receptor agonist | |
| US5340806A (en) | Composition containing organogermanium compound and immunity adjusting agent comprising the composition | |
| US5369120A (en) | Pharmaceutical composition of 7-((substituted)amino-8-((substituted)carbonyl)-(methylamino)-1-oxasp iro(4,5)decanes and L-dopa | |
| US2799619A (en) | Anti-excitatory compositions | |
| US3988461A (en) | Pharmaceutical composition for the treatment of Parkinson's disease | |
| JPS5921615A (ja) | 鎮痛剤組成物 | |
| US3348999A (en) | Compositions to enhance the learning rate and retention level in animals comprising 2-imino-5-phenyl-4-oxazolidinone and a relatively insoluble base | |
| US3354036A (en) | Method of producing depression | |
| US3994925A (en) | Salt of the silymarin group with aminopolyhydroxy alcohols |